Virion Therapeutics completes enrollment of first 2 cohorts of Phase 1b chronic hepatitis B trial of VRON-0200 for HBV functional cure
Virion Therapeutics, LLC announced that its Phase 1b clinical trial, evaluating VRON-0200 for HBV functional cure has completed enrollment in its first two cohorts. Specifically, 27 chronically HBV-infected patients on nucleos(t)ide antiviral therapy, have now received a single (Prime), or Prime and Boost, i.m. injection of VRON-0200. Virion has previously presented data from this study that showed that a single VRON-0200 injection was safe and well tolerated and was able to induce immune responses and anti-HBV activity despite the fact that most patients had highly impaired HBV immunity prior to treatment. Additionally, a third Cohort, the first to investigate VRON-0200 in combination with several investigational anti-HBV agents, is now underway.
Read the full press release here.
Source : Virion Therapeutics
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.